Targeting stromal cells to improve immune therapy for pancreatic cancer
Integration of stromal targeting agents with immune checkpoint therapy
['FUNDING_P01'] · JOHNS HOPKINS UNIVERSITY · NIH-11146709
This study is looking at ways to make immune therapies work better for people with pancreatic cancer by using special treatments that help immune cells get into the tumors and do their job more effectively.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11146709 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting specific components in the pancreatic tumor environment can enhance the effectiveness of immune therapies. By using agents that degrade hyaluronic acid and inhibit certain signaling pathways, the study aims to improve the infiltration and function of immune cells within pancreatic tumors. The approach involves testing combinations of these agents in mouse models to observe their effects on tumor growth and immune response. Patients may benefit from insights gained that could lead to more effective treatments for pancreatic ductal adenocarcinoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immune responses and better treatment outcomes for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar stromal targeting approaches, indicating potential for success in this area.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHENG, LEI — JOHNS HOPKINS UNIVERSITY
- Study coordinator: ZHENG, LEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.